XML 14 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2018
Jun. 30, 2018
Current assets:    
Cash and cash equivalents $ 93.3 $ 110.9
Marketable investment securities 74.2 69.7
Prepaid expenses 11.5 9.4
Inventory 35.9 34.3
Trade accounts receivable 119.1 99.5
Prepaid taxes 3.6  
Other receivables 4.3 3.8
Total current assets 341.9 327.6
Property, plant and equipment, net 60.0 43.2
Long-term marketable investment securities 24.2 30.7
Intangibles, net 734.2 455.2
Goodwill 413.3 318.6
Total assets 1,573.6 1,175.3
Current liabilities:    
Accounts payable 23.8 26.0
Accrued liabilities 76.4 68.3
Short-term contingent consideration 5.3 5.3
Deferred revenue 2.5 2.6
Total current liabilities 108.0 102.2
Unrecognized tax benefits 24.6 24.9
Other long-term liabilities 6.3 6.3
Contingent consideration 9.6 9.2
Long-term debt 258.0 9.3
Long-term deferred taxes 64.9 57.3
Total liabilities 471.4 209.2
Commitments and contingencies
Stockholders’ equity:    
Common stock, 74.7 and 70.6 shares outstanding at September 30, 2018 and June 30, 2018 respectively 0.7 0.7
Additional paid-in capital 1,052.4 915.4
Accumulated other comprehensive loss (4.3) (4.1)
Retained earnings 53.4 54.1
Total Myriad Genetics, Inc. stockholders’ equity 1,102.2 966.1
Total stockholders' equity 1,102.2 966.1
Total liabilities and stockholders’ equity $ 1,573.6 $ 1,175.3